ROG.SW - Roche Holding AG

Swiss - Swiss Delayed Price. Currency in CHF
345.55
+2.25 (+0.66%)
At close: 5:30PM CET
Stock chart is not supported by your current browser
Previous Close343.30
Open340.75
Bid0.00 x 0
Ask346.00 x 0
Day's Range340.30 - 346.55
52 Week Range255.95 - 346.55
Volume1,351,070
Avg. Volume1,701,712
Market Cap294.95B
Beta (5Y Monthly)0.39
PE Ratio (TTM)22.12
EPS (TTM)15.62
Earnings DateN/A
Forward Dividend & Yield9.00 (2.62%)
Ex-Dividend DateMar 19, 2020
1y Target Est259.86
  • PR Newswire

    Greenphire and Roche Team to Address Critical Clinical Trial Patient Convenience Issues at 11th Annual SCOPE Summit

    Greenphire, the global leader in financial software for clinical trials, today announced that it has teamed with top industry sponsor, Roche (SIX: RO, ROG; OTCQX: RHHBY), to address the top hurdles patients face when participating in clinical trials. The companies will co-present vital findings from a recent global trial survey on patient convenience, highlighting the need to alleviate financial and logistical burdens from participants in order to maximize retention and engagement.

  • Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
    Zacks

    Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails

    AbbVie (ABBV) and Allergan (AGN) announce Q4 results.

  • GlobeNewswire

    China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

  • Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
    Zacks

    Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

    Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.

  • PR Newswire

    Promedior Announces Completion of Acquisition by Roche

    Promedior, Inc. today announced the successful completion of its previously announced sale to Roche (SIX: RO, ROG; OTCQX: RHHBY). With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an upfront cash payment of USD 390 million, with additional contingent payments of up to USD 1 billion to be made based on the achievement of certain predetermined development, regulatory and commercial milestones.

  • Coronavirus outbreak begins to disrupt booming China drug trials
    Reuters

    Coronavirus outbreak begins to disrupt booming China drug trials

    The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc. China has imposed a virtual lockdown on Wuhan and severely restricted travel in its wider province of Hubei and some other cities.

  • These Pharma Giants Took A Hit On Two More Alzheimer's Failures
    Investor's Business Daily

    These Pharma Giants Took A Hit On Two More Alzheimer's Failures

    Shares of Eli Lilly and Roche slipped early Monday after the pharma companies' experimental Alzheimer's treatments, solanezumab and gantenerumab, failed in a genetic form of the disease.

  • Lilly Reports Disappointing Data on Alzheimer's Candidate
    Zacks

    Lilly Reports Disappointing Data on Alzheimer's Candidate

    Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.

  • Roche, Lilly drugs fail to halt gene-driven Alzheimer's disease
    Reuters

    Roche, Lilly drugs fail to halt gene-driven Alzheimer's disease

    Experimental drugs from Roche and Eli Lilly failed to halt Alzheimer's disease in their latest test, the companies said on Monday, in a blow to people whose genes make them particularly vulnerable to the illness. Pursuit of an Alzheimer's remedy, which would inevitably reap drugmakers billions of dollars, has been marked by more than 100 failures, although researchers still hope to tame a condition that affects nearly 6 million Americans, more than 40 million people worldwide, and which is growing more prevalent. The study of Roche's gantenerumab and Eli Lilly's solanezumab spearheaded by Washington University in St. Louis focused on rare autosomal dominant Alzheimer's disease, which is caused by gene mutations that follow generations of families.

  • Barrons.com

    Lilly and Biogen Stocks Get Hit as Another Alzheimer’s Treatment Fails a Trial

    Eli Lilly said its drug solanezumab had failed in a trial of patients with dominantly inherited Alzheimer’s disease.

  • GlobeNewswire

    Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer’s disease (AD). This form of AD, known as autosomal dominant AD (ADAD), accounts for less than 1% of all cases of the disease.1 The study, sponsored by Washington University School of Medicine in St. Louis, US, did not show a significant slowing of the rate of cognitive decline in people treated with investigational medicine gantenerumab as measured by the novel DIAN Multivariate Cognitive Endpoint, compared with placebo.

  • Business Wire

    Genentech Provides Topline Results From Investigator-Led Phase II/III Trial With Gantenerumab in Rare Inherited Form of Alzheimer’s Disease

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer’s disease (AD). This form of AD, known as autosomal dominant AD (ADAD), accounts for less than 1% of all cases of the disease. The study, sponsored by Washington University School of Medicine in St. Louis, did not show a significant slowing of the rate of cognitive decline in people treated with investigational medicine gantenerumab as measured by the novel DIAN Multivariate Cognitive Endpoint, compared with placebo. Overall, gantenerumab's safety profile in DIAN-TU-001 was consistent with that from other clinical trials of the investigational medicine and no new safety issues were identified.

  • Financial Times

    Roche and Eli Lilly drugs fail ‘inherited’ Alzheimer’s trial

    Alzheimer’s drugs made by Eli Lilly and Roche have disappointed in a late-stage trial, dealing another blow to the most common hypothesis about what causes the devastating degenerative disease. An initial analysis of the trial results found the drugs both failed to slow cognitive decline, as measured by tests of thinking and memory, in patients who have a rare inherited form of Alzheimer’s that can cause deterioration in their 40s or 50s — or even earlier. The trial — which followed 197 patients for up to seven years — was an important attempt to slow the symptoms of Alzheimer’s before they manifested.

  • This Biotech Stock Fell, Then Rose, And Prodded Biogen Into A Two-Day Run
    Investor's Business Daily

    This Biotech Stock Fell, Then Rose, And Prodded Biogen Into A Two-Day Run

    Shares of PTC Therapeutics slipped, then rose Thursday after the biotech company unveiled disappointing Phase 3 results for its Biogen-rivaling experimental spinal muscular atrophy drug, risdiplam.

  • GlobeNewswire

    Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from the pivotal Part 2 of SUNFISH, a global placebo-controlled study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study showed that change from baseline in the primary endpoint of the Motor Function Measure scale (MFM-32)1 was significantly greater in people treated with risdiplam, compared to placebo (1.55 point mean difference; p=0.0156).

  • Business Wire

    Genentech’s Risdiplam Showed Significant Improvement in Motor Function in People Aged 2-25 With Type 2 or 3 Spinal Muscular Atrophy

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented 1-year data from the pivotal Part 2 of SUNFISH, a global placebo-controlled study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study showed that change from baseline in the primary endpoint of the Motor Function Measure 32 scale (MFM-32)* was significantly greater in people treated with risdiplam, compared to placebo (1.55 point mean difference; p=0.0156). The Revised Upper Limb Module (RULM),** a key secondary endpoint, also showed an improvement (1.59 point difference; p=0.0028). Safety for risdiplam in the SUNFISH study was consistent with its known safety profile. Data were presented at the 2nd International Scientific and Clinical Congress on Spinal Muscular Atrophy from February 5-7 in Evry, France.

  • Biogen Reports Strong 4th-Quarter Earnings and Growth Potential
    GuruFocus.com

    Biogen Reports Strong 4th-Quarter Earnings and Growth Potential

    Biotech giant continues increasing profits and products while trading at a low valuation Continue reading...

  • Roche says closed Chinese cities hinder virus diagnostics test deliveries
    Reuters

    Roche says closed Chinese cities hinder virus diagnostics test deliveries

    Swiss drugmaker Roche is struggling to deliver diagnostic tests for the coronavirus to large Chinese cities after Communist Party rulers halted people from entering and leaving in a bid to halt the spreading outbreak. "Getting the goods to hospitals has been a real challenge," Roche diagnostics boss Thomas Schinecker told reporters on Thursday. Chief Executive Severin Schwan said Roche was the first company to supply tests to diagnose the virus, thought to have originated in a food market in the city of Wuhan with about 11 million people, and has now seen thousands of cases and at least 170 deaths in China.

  • GlobeNewswire

    Roche reports very strong results in 2019

    Basel, 30 January 2020  Group sales increase 9%1 at constant exchange rates and 8% in Swiss francs, driven by new products, more than compensating for impact of competition.

  • GlobeNewswire

    Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.

  • Business Wire

    Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the completion of a supplemental Biologics License Application (sBLA) submission to the U.S. Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. In July 2018, the FDA granted Breakthrough Therapy Designation for Tecentriq in combination with Avastin in HCC based on data from an ongoing Phase Ib trial.

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: ...

  • Business Wire

    Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-invasive Urothelial Cancer

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.

  • GlobeNewswire

    Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified. “Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development.